Cargando…

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial

PURPOSE: The insulin-like growth factor (IGF) system is modifiable by diet and lifestyle, and has been linked to prostate cancer development and progression. METHODS: We conducted a prospective cohort study of 621 men diagnosed with localized prostate cancer to investigate the associations of dietar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Er, Vanessa, Biernacka, Kalina, Simpkin, Andrew J., Martin, Richard M., Jeffreys, Mona, Emmett, Pauline, Gilbert, Rebecca, Avery, Kerry N. L., Walsh, Eleanor, Davis, Michael, Donovan, Jenny L., Neal, David E., Hamdy, Freddie C., Holly, Jeff M. P., Lane, J. Athene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501895/ https://www.ncbi.nlm.nih.gov/pubmed/28646365 http://dx.doi.org/10.1007/s10552-017-0910-2

Ejemplares similares

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification
por: Hackshaw-McGeagh, Lucy E, et al.
Publicado: (2015)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
por: Rosario, Derek J, et al.
Publicado: (2012)

Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
por: Donovan, Jenny L., et al.
Publicado: (2018)

Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study
por: Zuccolo, Luisa, et al.
Publicado: (2013)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2015)

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)
por: Lane, Janet Athene, et al.
Publicado: (2022)

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer
por: Noble, Sian M., et al.
Publicado: (2020)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial
por: Biernacka, Kalina M., et al.
Publicado: (2019)

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial
por: Johnston, Thomas J., et al.
Publicado: (2017)

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
por: Wade, Julia, et al.
Publicado: (2020)

The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals
por: Avery, Kerry NL, et al.
Publicado: (2014)

Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study
por: Horwood, Jeremy P, et al.
Publicado: (2014)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
por: Dimitropoulou, P, et al.
Publicado: (2011)

Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial
por: Walsh, Eleanor I., et al.
Publicado: (2016)

Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
por: Bryant, Richard J., et al.
Publicado: (2015)

Evaluating best practice in informed consent discussions: a new method of evaluating information provision and patient understanding during trial recruitment consultations
por: Wade, Julia, et al.
Publicado: (2013)

Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?
por: Harrison, Sean, et al.
Publicado: (2016)

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial
por: Lane, Athene J, et al.
Publicado: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study
por: Catto, J W F, et al.
Publicado: (2011)

Exploring treatment preferences facilitated recruitment to randomized controlled trials
por: Mills, Nicola, et al.
Publicado: (2011)

Addressing patient treatment preferences at trial recruitment
por: Mills, Nicola, et al.
Publicado: (2011)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
por: Sanghera, S., et al.
Publicado: (2020)

Evaluation of source data verification in a multicentre cancer trial (PROTECT)
por: Lane, J Athene, et al.
Publicado: (2013)

Do people who choose their treatment in a large randomised trial with parallel preference groups differ at baseline from those who agree to random treatment allocation? Results from the protect study
por: Mills, Nicola, et al.
Publicado: (2015)

Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle
por: Holly, Jeff M. P., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
por: Keeney, Edna, et al.
Publicado: (2022)

Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
por: Gilbert, Rebecca, et al.
Publicado: (2018)

He protec but he also attac – Inflammasomes swinging the sword()
por: Kattner, Aila Akosua
Publicado: (2023)

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study
por: Young, Grace J, et al.
Publicado: (2017)

ProTec - A Normal-conducting Cyclinac for Proton Therapy Research and Radioisotope Production
por: Apsimon, Robert, et al.
Publicado: (2015)

IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells
por: Mansor, Rehanna, et al.
Publicado: (2020)

Correction: IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells
por: Mansor, Rehanna, et al.
Publicado: (2023)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Systemic Metabolism, Its Regulators, and Cancer: Past Mistakes and Future Potential
por: Holly, Jeff M. P., et al.
Publicado: (2019)

The Neglected Insulin: IGF-II, a Metabolic Regulator with Implications for Diabetes, Obesity, and Cancer
por: Holly, Jeff M. P., et al.
Publicado: (2019)

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen
por: Harrison, Sean, et al.
Publicado: (2020)

Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk
por: Lewis, Sarah J., et al.
Publicado: (2010)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
por: Kim, Isaac Yi
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r49pq33r7990221mqbphhc02pb